Company Encyclopedia
View More
name
FUSEN PHARM
01652.HK
Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian oral solutions and Shuanghuanglian injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers small and large volume injections, oral liquids, tablets, capsules, granules, traditional Chinese medicine extracts, and chemical synthesis. In addition, the company provides business management and consulting services; and engages in the sale of construction material and electricity.
1.450 T
01652.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
PharmaceuticalsIndustry
Industry Ranking48/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-40.36%E
    • Profit Margin-72.61%E
    • Gross Margin38.63%B
  • Growth ScoreE
    • Revenue YoY-43.28%E
    • Net Profit YoY-95.42%E
    • Total Assets YoY-6.11%D
    • Net Assets YoY-32.26%E
  • Cash ScoreE
    • Cash Flow Margin-137.73%D
    • OCF YoY-43.28%E
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreD
    • Gearing Ratio71.99%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The Hang Seng Index fell 0.89% at midday, and the Hang Seng Tech Index dropped 1.91%

    36Kr learned that the Hang Seng Index fell 0.89% during the midday break, and the Hang Seng Tech Index dropped 1.91%; the semiconductor, consumer, and construction sectors led the decline, with MCC and Hua Hong Semiconductor falling over 6%, and POP MART dropping over 3%; the pharmaceutical and biotechnology, retail, and oil and petrochemical sectors saw the largest gains, with FUSEN PHARM rising over 59%, Guoquan increasing over 7%, and China Petroleum & Chemical Corporation rising over 1%; southbound funds had a net purchase of HKD 4.759 billion

    36Kr·
    HK
    09992
    +1.67%
    SH
    601618
    +3.04%
    HK
    01618
    +3.93%
    36Kr·
    HK
    09992
    +1.67%
    SH
    601618
    +3.04%
    HK
    01618
    +3.93%

    Hong Kong Stock Midday Review | Hang Seng Index fell 0.89% in the morning session, Hang Seng Biotechnology Index rebounded 2.16%

    The Hong Kong Hang Seng Index fell 0.89% in the morning session, reporting 26,050 points, while the Hang Seng Tech Index dropped 1.91%. The Hang Seng Biotechnology Index rebounded by 2.16%. The newly listed stock DEEPEXI TECH surged over 20%, doubling its price within three days of listing. Ying'en Biotechnology-B rose 10.88%, and 3SBIO increased by over 10%. FUSEN PHARM saw an intraday increase of nearly 74%. Ansteel fell over 8%, and China Everbright Bank dropped 5%

    Zhitong·
    HK
    01652
    0.00%
    HK
    01384
    +0.76%
    HK
    01530
    -0.47%
    Zhitong·
    HK
    01652
    0.00%
    HK
    01384
    +0.76%
    HK
    01530
    -0.47%

    Understanding the Market | FUSEN PHARM surged nearly 74% during the session as Enzalutamide soft capsules were approved for market launch, and Metformin and Ertugliflozin tablets are expected to be selected for national centralized procurement

    FUSEN PHARM's stock price surged nearly 74% during the trading session, and as of the time of writing, it has risen by 49.28%, trading at HKD 1.03, with a transaction volume of HKD 10.3715 million. In terms of news, FUSEN PHARM announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration of the People's Republic of China for the listing application of "Enzalutamide Soft Capsules," which is approved for the treatment of the following diseases: adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis; and adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms and have not received chemotherapy after failure of androgen deprivation therapy (ADT). FUSEN PHARM also announced that its product Metformin and Ertugliflozin Tablets (I) (500mg Metformin Hydrochloride and 5mg Ertugliflozin) is expected to win a bid in the recently announced results of the 11th batch of national centralized drug procurement in China. It is reported that FUSEN PHARM announced in September this year that the listing application for its developed "Metformin and Ertugliflozin Tablets (I)" has been approved by the National Medical Products Administration of China

    Zhitong·
    HK
    01652
    0.00%
    Zhitong·
    HK
    01652
    0.00%

    FUSEN PHARM: "Enzalutamide Soft Capsules" Approved for Market Launch

    FUSEN PHARM announced that its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has developed "Enzalutamide Soft Capsules," which have been approved for marketing by the National Medical Products Administration of China. This drug is used for the treatment of high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and metastatic castration-resistant prostate cancer (CRPC) after failure of androgen deprivation therapy. Enzalutamide is an androgen receptor inhibitor that can inhibit the proliferation of prostate cancer cells and induce cell death

    Zhitong·
    HK
    01652
    0.00%
    Zhitong·
    HK
    01652
    0.00%

    FUSEN PHARM: Metformin and Ertugliflozin Tablets (I) intends to win the bid for the 11th batch of national centralized drug procurement in China

    According to the Zhitong Finance APP, FUSEN PHARM announced that one of its products is expected to win the bid in the results of China's 11th national centralized drug procurement tender on October 27, 2025: Metformin and Ertugliflozin Tablets (I) (500mg Metformin Hydrochloride and 5mg Ertugliflozin)

    Zhitong·
    HK
    01652
    0.00%
    Zhitong·
    HK
    01652
    0.00%
    © 2025 Longbridge｜Disclaimer